Ignite Creation Date:
2024-05-06 @ 11:30 AM
Last Modification Date:
2024-10-26 @ 12:46 PM
Study NCT ID:
NCT03535740
Status:
COMPLETED
Last Update Posted:
2023-08-25
First Post:
2018-05-09
Brief Title:
A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive ALK Advanced Non-Small-Cell Lung Cancer NSCLC Progressed on Alectinib or Ceritinib
Sponsor:
Ariad Pharmaceuticals
Organization:
Takeda
Conditions & Keywords Data
Conditions:
| Name |
|---|
| ALK-positive Advanced NSCLC |
Keywords:
| Name | View |
|---|---|
| Drug Therapy | View |